MS Center of California
Laguna Hills, California, United States
Research institute in Laguna Hills, California
24012 Calle De La Plata, Laguna Hills, CA 92653
About MS Center of California
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Hoffmann-La Roche
4
Sanofi
2
Allergan
1
Genentech, Inc.
1
MedDay Pharmaceuticals SA
1
Clinical Trials at MS Center of California
During the past decade, MS Center of California conducted 5 clinical trials. In the 10-year time frame, 5 clinical trials started and 3 clinical trials were completed, i.e. on
average, 60% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 1 clinical trials were completed. i.e. 33.3%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis
2011-03-02
2022-12-31
Completed
735
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis
2011-08-31
2022-12-31
Completed
821
An Adult Spasticity Registry of OnabotulinumtoxinA Treatment
2013-10-16
2017-10-09
Completed
744
Expanded Access Program for Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis
No longer available
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
2016-12-01
2020-04-23
Terminated
642
A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis
2018-05-28
2026-12-04
Active, not recruiting
927
Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168)
2020-06-11
2023-08-01
Active, not recruiting
900
Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168)
2020-08-13
2024-08-01
Recruiting
990
Clinical Trials Sponsors and Collaborators
Out of the total clinical trials conducted in "MS Center of California" #1 sponsor was "Hoffmann-La Roche" with 4 trials, followed by "Sanofi" with 2 trials
sponsored, "Allergan" with 1 trials sponsored, "Genentech, Inc." with 1 trials sponsored and "MedDay Pharmaceuticals SA"
with 1 trials sponsored. Other sponsors include -5 different institutions and
companies that sponsored additional 5 trials in total.
Clinical Trials Conditions at MS Center of California
According to Clinical.Site data, the most researched conditions in "MS Center of California" are
"Multiple Sclerosis" (3 trials), "Relapsing Multiple Sclerosis" (2 trials), "Multiple Sclerosis, Primary Progressive" (1 trials), "Muscle Spasticity" (1 trials) and "Primary Progressive Multiple Sclerosis" (1 trials). Many other conditions were trialed in "MS Center of California" in a lesser frequency.
Clinical Trials Intervention Types at MS Center of California
Most popular intervention types in "MS Center of California" are "Drug" (9 trials) and "Other" (1 trials). Other intervention types were less common.
The name of intervention was led by "Ocrelizumab" (5 trials), "Placebo" (2 trials), "Tolebrutinib" (2 trials), "Interferon beta-1a" (1 trials) and "Interferon beta-1a-matching placebo" (1 trials). Other intervention names were less common.
Clinical Trials Genders at MS Center of California
The vast majority of trials in "MS Center of California" are
9 trials for "All" genders.
Clinical Trials Status at MS Center of California
Currently, there are NaN active trials in "MS Center of California".
undefined are not yet recruiting,
2 are recruiting,
2 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 3 completed trials in MS Center of California,
undefined suspended trials,
and 1 terminated clinical trials to date.
Out of the total trials that were conducted in MS Center of California, 0 "Phase 1"
clinical trials were conducted, 0 "Phase 2" clinical
trials and 7 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 0 trials that are defined as “Not Applicable".